Lv7
4430 积分 2021-12-06 加入
Innovative antibody therapeutic development in China compared with the USA and Europe
11小时前
已关闭
PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
3个月前
已完结
The antibody–drug conjugate landscape
6个月前
已完结
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
7个月前
已完结
Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial
7个月前
已完结
Promising anti-IL-6 therapy for atherosclerosis
7个月前
已完结
HERMES: Effects Of Ziltivekimab Versus Placebo On Morbidity And Mortality In Patients With Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation
7个月前
已完结
ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK ASSESSMENT: An American Society for Preventive Cardiology Clinical Practice Statement
7个月前
已完结
Radiotheranostic landscape: A review of clinical and preclinical development
8个月前
已完结
Atherosclerotic Coronary Plaque Regression and Risk of Adverse Cardiovascular Events
11个月前
已完结
皖公网安备34019202002308
